TRANSFORMED INDOLENT B-CELL NON-HODGKIN LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA
Clinical trials for TRANSFORMED INDOLENT B-CELL NON-HODGKIN LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new TRANSFORMED INDOLENT B-CELL NON-HODGKIN LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for TRANSFORMED INDOLENT B-CELL NON-HODGKIN LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental combo aims to supercharge immune cells against Hard-to-Treat lymphoma
Disease control OngoingThis early-phase trial tests whether adding an experimental drug (NKTR-255) to standard CAR-T cell therapy can improve outcomes for adults with large B-cell lymphoma that has returned or not responded to treatment. About 27 participants will receive the combination to see if it i…
Matched conditions: TRANSFORMED INDOLENT B-CELL NON-HODGKIN LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 26, 2026 08:03 UTC
-
Promising combo aims to stop aggressive lymphoma in its tracks
Disease control OngoingThis study tests whether adding the drug venetoclax to standard chemotherapy can help prevent high-grade B-cell lymphomas from returning or getting worse. About 363 adults with specific aggressive lymphoma types will receive either the usual chemo or the usual chemo plus venetocl…
Matched conditions: TRANSFORMED INDOLENT B-CELL NON-HODGKIN LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 07:53 UTC